Cytokinetics has been granted a patent for compounds of Formula (I) and their pharmaceutically acceptable salts. The patent also covers compositions and methods of using these compounds. GlobalData’s report on Cytokinetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Cytokinetics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Cytokinetics, NSAID cancer drugs was a key innovation area identified from patents. Cytokinetics's grant share as of April 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11964967B2) discloses a compound of Formula (I) and its various derivatives, including those where X is —CH2— or —O—, and R3 is substituted or unsubstituted alkyl, cycloalkyl, haloalkyl, —CHF2, or cyclopropyl. The patent also covers pharmaceutical compositions containing these compounds along with a pharmaceutically acceptable excipient.

Furthermore, the patent describes methods for treating heart diseases such as hypertrophic cardiomyopathy, heart failure with preserved ejection fraction, diastolic dysfunction, restrictive cardiomyopathy, myocardial infarction, and various other conditions related to cardiac health. It also includes methods for treating diseases associated with specific cardiac conditions like small left ventricular cavity, hyperdynamic left ventricular contraction, myocardial ischemia, and cardiac fibrosis by administering the disclosed compound or its pharmaceutically acceptable salt. Additionally, the patent covers a method for inhibiting a cardiac sarcomere by contacting it with the compound mentioned in the claims.

To know more about GlobalData’s detailed insights on Cytokinetics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies